Patents by Inventor Bruce Wentworth

Bruce Wentworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
    Patent number: 10111962
    Abstract: Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3? untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of mytonic dystrophy type I (DM1).
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 30, 2018
    Assignee: Genzyme Corporation
    Inventors: Andrew Leger, Bruce Wentworth, Carol A. Nelson, Timothy E. Weeden, Nicholas Clayton, Seng Cheng
  • PEPTIDE-LINKED MORPHOLINO ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF MYOTONIC DYSTROPHY
    Publication number: 20150238627
    Abstract: Provided herein are peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3? untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK) and methods for systemic administration of the same for the treatment of mytonic dystrophy type I (DM1).
    Type: Application
    Filed: September 24, 2013
    Publication date: August 27, 2015
    Applicant: Genzyme Corporation
    Inventors: Andrew Leger, Bruce Wentworth, Carol A. Nelson, Timothy E. Weeden, Nicholas Clayton, Seng Cheng
  • Skeletal musle-derived cells and methods related thereto
    Publication number: 20070086987
    Abstract: The disclosure provides methods of propagating skeletal muscle cell (SkMC) cultures enriched in differentiation-competent myoblasts that express normal levels of CD56 and reduced levels of desmin. The methods comprise culturing SkMCs in a mitogen-rich cell culture medium supplemented with TGF-?. The disclosure also provides therapeutic methods utilizing SkMCs propagated in TGF-?, e.g., methods of treating myocardial infarction by transplantation of autologous or allogeneic SkMCs.
    Type: Application
    Filed: November 15, 2004
    Publication date: April 19, 2007
    Inventors: Peter Yaeger, Jeffrey Stewart, Bruce Wentworth